Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Gaviscon Double Action - Philippines FDA Drug Approval Details

Approvals/Philippines FDA/Gaviscon Double Action

Approved

STANDARD

Gaviscon Double Action

Reckitt Benckiser Healthcare (UK) Limited🇵🇭 Food and Drug Administration - Philippines

Approval Date: Jul 14, 2025
Approval ID: 908f93e39204d7aa
Company: Reckitt Benckiser Healthcare (UK) Limited
Type: Standard

Approval Details

Approval Id: 908f93e39204d7aa
Drug Approval Philippines Name: Gaviscon Double Action
Product Name: Gaviscon Double Action
Registration Number: DR-XY43337
Brand Name: Gaviscon Double Action
Generic Name: Sodium Alginate + Sodium Bicarbonate + Calcium Carbonate
Dosage Form: Suspension
Dosage Strength: 500mg / 213 mg / 325mg per 10mL
Manufacturer: Reckitt Benckiser Healthcare (UK) Limited
Importer: Reckitt Benckiser Healthcare (Philippines) Inc.
Company Detail Path: /organization/reckitt-benckiser-healthcare-uk-limited
Issuance Date: 27 October 2023
Expiry Date: 03 April 2029
Pharmacologic Category: Antacid
Classification: Over-the-Counter (OTC)

Active Ingredients

Approved

Quick Info

Agency

Philippines FDA

Country

🇵🇭

Approval Date

Jul 14, 2025

Approval ID

908f93e39204d7aa

Type

Standard

Back to Philippines FDA Approvals